Publication: Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
Date
2018-06-01T00:00:00Z
Authors
Aypar, Eda
Izzettin, FİKRET VEHBİ
Aki, Sahika Zeynep
SANCAR, MESUT
Yegin, Zeynep Arzu
Turkoz-Sucak, Gulsan
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.
Description
Keywords
Citation
Aypar E., Izzettin F. V. , Aki S. Z. , SANCAR M., Yegin Z. A. , Turkoz-Sucak G., -Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib-, JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.24, ss.281-289, 2018